ResMed (NYSE:RMD) saw its shares rise 8% intra-day today following a robust first-quarter fiscal 2025 report that exceeded Street expectations. The sleep and respiratory care device maker posted adjusted earnings per share of $2.20 for the quarter, above the Street estimate of $2.05. Revenue increased by 11% year-over-year, reaching $1.22 billion and topping projections of $1.19 billion.
ResMed’s operational focus contributed to notable margin gains, with gross margin expanding by 420 basis points to 58.6% and adjusted gross margin rising by 320 basis points to 59.2%. Income from operations also saw a substantial 34% increase compared to the same period last year.